FOUNDER & MANAGING DIRECTOR

Robert began his data science career by accident. He was trying to fix a problem. The problem was with a commercial E. coli fermentation process. The solution came from studying biology, chemistry, engineering, small-scale development data, and analytical data.

Robert honed his troubleshooting skills while working for large and small biotech companies, including Scios, Johnson & Johnson, Coherus Bioscience, and Omniox. Twenty years after that first E. coli fermentation discovery, Robert is now sharing his techniques with employees, clients, and colleagues.

Andy has nearly 20 years of experience in innovative medicine discovery and drug development in a variety of therapeutic areas. Since 2013, he has served on leadership teams at private and public biotechnology companies.

He is currently the Head of Strategy, Portfolio, and Business Development at Empirico (San Diego). Empirico is leveraging its deep expertise in the analyses of expansive biological datasets, human genetics, and programmable biology to power novel target discovery programs and have partnerships with Ionis and AbCellera.

Prior to Empirico, Andy was SVP, Preclinical Research and Development at Millendo Therapeutics where he led nonclinical development for multiple, novel experimental treatments for rare endocrine disorders. Before that, he was VP of Pharmacology & DMPK at Arcelyx where he made multidisciplinary contributions to the company’s drug discovery, development, and partnering efforts. For several years he served as program manager for IBSRELA (tenapanor), a minimally systemic inhibitor of NHE3.

Andy’s primary focus is on building and executing with great colleagues to deliver new medicines to patients and familes in need.

Imad brings in years of experience in organic chemistry , small molecules, pharmaceuticals, diagnostics, R&D, and cGMP manufacturing. He has a deep understanding of drug discovery and novel drug design—inventor of new drug entities on various patents in metabolic and inflammatory diseases. Imad has extensive experience in medicinal chemistry, multi-step organic synthesis, and process development.

Imad enjoys the art of novel design, synthesis of small molecules, drug-Haptens, drug-conjugates, and Immunogens for IVD prodcuts.

Imad has many years of experience leading groups of scientists. He excels in project management and has led multiple projects in parallel from inception to completion.

Carl Dowds, Ph.D., is a program management leader and scientific expert in the design and the approval of genotype analysis software products. He is a technical expert for those who need medical diagnostic products utilizing genome-wide data that analyzes and interprets adverse biological events. He communicates with end-users, software developers, software testers, and the FDA to obtain product approval.